Dan Geffken is the founder of Zikani Therapeutics. Zikani Therapeutics has raised $8M in total funding. Latest round: Series A.
Daniel E. Geffken is the Interim Chief Financial Officer at Eloxx, engaged through Danforth Advisors, which he co-founded. He has over 30 years of financial experience in biopharmaceutical companies, serving as CFO for various firms and participating in eleven IPOs. He holds a B.S. from The Wharton School and an M.B.A. from Harvard Business School. Zikani Therapeutics, an anti-infective company where Dr. Roger Clark previously worked, was acquired by Eloxx in April 2021.
Full founder directory · Investor directory · Company funding database · Fundraising library